Learn about how expedited regulatory approval programs offered by the EMA and FDA can significantly reduce the Clinical Development time for new anti-cancer drugs. Our latest article dives into the correlation between clinical development time and regulatory approval programs and how PLG's expertise in understanding the market landscape can save both time and cost to bring new anti-cancer therapies to patients.